Professor, Consultant Interventional Cardiology
Lund University
Lund, Sweden
Dr David Erlinge is Professor of Cardiology at Lund University, Sweden Prof Erlinge is an interventional cardiologist focusing on PCI with a clinical interest in acute coronary syndromes. He is chairman of the Swedish PCI register (SCAAR) member of the board of SWEDEHEART.
He has been involved in the developing and leading registry based randomized clinical trials (RRCT) from TASTE, IFR-SWEDEHEART, DETO2X and was the leader of the pharmaceutical RRCT VALIDATE-SWEDEHEART and the diagnostic vunerable plaque trial PROSPECT II.
Disclosure(s): No financial relationships to disclose
5 Year Data from the SWEDHART and DEFINE: What are the Take Home Message?
Saturday, March 9, 2024
9:57 AM – 10:05 AM ET
Saturday, March 9, 2024
10:21 AM – 10:36 AM ET
CRT 2024 | Faculty Assignment [OUS]
Saturday, March 9, 2024
9:00 AM – 9:00 PM ET
Update on DynamX Bioadaptor Trial Results
Sunday, March 10, 2024
11:19 AM – 11:27 AM ET
Discussion: Is there a Role/Need for Bioresorbable and/or Bioadaptor Platforms?
Sunday, March 10, 2024
11:51 AM – 12:06 PM ET
Sunday, March 10, 2024
3:18 PM – 3:26 PM ET
Sunday, March 10, 2024
3:26 PM – 3:41 PM ET
ATHEROSCLEROSIS THERAPEUTIC OPTIONS AND MANAGEMENT
Sunday, March 10, 2024
5:08 PM – 6:51 PM ET
Panel Discussion: Atherosclerosis Therapeutic Options and Management
Sunday, March 10, 2024
6:36 PM – 6:51 PM ET